Breaking News

Unemployment Insurance Weekly Claims Report Agents Encounter and Seize Cloned Border Patrol Vehicle Attempting Illegal Entry USAID Announces Expansion in the Pacific Region and Reaffirms Commitment to Bolster Resilience in the Pacific Islands at the 2022 U.S.-Pacific Island Country Summit | Press Release Governor Abbott Deploys Additional Resources To Florida To Assist Hurricane Ian Response Efforts | Office of the Texas Governor Flag Officer Assignments > U.S. Department of Defense > Release USCIS Awards FY 2022 Citizenship and Integration Grants Governor Newsom Deploys Emergency Personnel to Florida to Aid With Response to Hurricane Ian VMWare Releases Guidance for VirtualPITA, VirtualPIE, and VirtualGATE Malware Targeting vSphere

Issued: London, UK

GlaxoSmithKline plc (the ‘Company’) today announces that Sir Christopher Gent will step down as Chairman of GSK at the Company’s Annual General Meeting on 7 May 2015. He will be succeeded by Sir Philip Hampton with effect from the end of the AGM.

Sir Philip joined GSK’s Board as an independent Non-Executive Director on 1 January 2015, and will become Deputy Chairman on 1 April 2015. Sir Philip chairs the Company’s Nominations Committee. He will remain Chairman of RBS until 31 August 2015.

In addition, Tom de Swaan, independent Non Executive Director, is not seeking re-election to the Board at the AGM. He has been a Board member for 9 years and is currently Chairman of the Remuneration Committee and a member of the Audit & Risk Committee (of which he was previously Chairman), and the Nominations Committee. A successor for Mr de Swaan as Chairman of the Remuneration Committee will be announced in due course.

Jing Ulrich has decided not to stand for re-election to the Board at the AGM. 

V A Whyte
Company Secretary

Notes

With effect from the end of the Company’s AGM on 7 May 2015, the composition of the Board of GSK will be as follows:

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit our about us section.

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Risk factors’ in the company’s Annual Report on Form 20-F for 2013.

Source link